Acumen Research and Consulting Ophthalmic Drugs Market | Page 3

Retinal disorder has been estimated as the largest segment and, due to the increasing prevalence of diabetic retinopathy, is considered to be the fastest- growing segment of the disease. Eye drops led the market in 2018, with the most cost-effective CAGR compared to other forms of dosage being projected. The largest share of prescription drugs was in 2018, as they are seen as more effective. Due to the easy accessibility of OTC drugs, OTC type is said to be the fastest growing segment during the predicted time period. The market was led by North America in 2018 as demand for the treatment of dry eyes and glaucoma was growing. Different organizations’ awareness programs and the increase in disposable incomes are projected to be the most rapidly growing regional market during the forecast period. Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs Key Players & Strategies The Ophthalmic Drugs market is consolidated with a large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview, and revenues. The key players of the market are ALLERGAN PLC; Pfizer, Inc.; Santen Pharmaceutical Co., Ltd.; Johnson & Jean – Services, Inc.; Merck Sharp & Dohme Corp.; and Genentech, Inc. AG; Bausch & Lomb, Inc.; Regeneron Pharmaceutical, Inc., among others. Santen Pharmaceuticals has been approved for the treatment of Severe Vernal Keratoconjunctivitis in pediatric patients by the Committee of Human Medicinal Products (CHMP) in 2017 for the marketing of its product, cyclosporine, in Europe. In the same year Genentech, Inc. was approved for the treatment of Would like to place an order or any question, please feel free to contact at [email protected] | [phone]